ATE309246T1 - 1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate - Google Patents

1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate

Info

Publication number
ATE309246T1
ATE309246T1 AT03709786T AT03709786T ATE309246T1 AT E309246 T1 ATE309246 T1 AT E309246T1 AT 03709786 T AT03709786 T AT 03709786T AT 03709786 T AT03709786 T AT 03709786T AT E309246 T1 ATE309246 T1 AT E309246T1
Authority
AT
Austria
Prior art keywords
alkyl
pyrimidine
imidazo
heteroaryl
aryl
Prior art date
Application number
AT03709786T
Other languages
English (en)
Inventor
Alistair Lochead
Mourad Saady
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE309246T1 publication Critical patent/ATE309246T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03709786T 2002-02-28 2003-02-26 1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate ATE309246T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02290487A EP1340759A1 (de) 2002-02-28 2002-02-28 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
PCT/EP2003/002652 WO2003072580A1 (en) 2002-02-28 2003-02-26 1-[ALKYL], 1-[HETEROARYL)ALKYL] AND 1-[ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMADAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
ATE309246T1 true ATE309246T1 (de) 2005-11-15

Family

ID=27675771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709786T ATE309246T1 (de) 2002-02-28 2003-02-26 1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate

Country Status (23)

Country Link
US (2) US7429663B2 (de)
EP (2) EP1340759A1 (de)
JP (1) JP4484524B2 (de)
KR (1) KR100935262B1 (de)
CN (1) CN100441581C (de)
AR (1) AR038620A1 (de)
AT (1) ATE309246T1 (de)
AU (1) AU2003214127C1 (de)
BR (1) BR0308106A (de)
CA (1) CA2474875C (de)
DE (1) DE60302220T2 (de)
DK (1) DK1480981T3 (de)
EA (1) EA007459B1 (de)
ES (1) ES2250876T3 (de)
IL (1) IL163288A (de)
MX (1) MXPA04008365A (de)
NO (1) NO329756B1 (de)
NZ (1) NZ534467A (de)
PL (1) PL372664A1 (de)
SI (1) SI1480981T1 (de)
TW (1) TWI305534B (de)
WO (1) WO2003072580A1 (de)
ZA (1) ZA200406154B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004043A (es) * 2003-10-10 2006-06-28 Pfizer Prod Inc 2h-[1,2,4]triazolo[4,3-a]pirazinas sustituidas como inhibidores de la glucogeno sintetasa cinasa 3.
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2296474A1 (de) * 2008-05-30 2011-03-23 Merck Sharp & Dohme Corp. Neue substituierte indole
EP2138494A1 (de) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Alkylpyrimidin-4-one-Derivate
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101745028B1 (ko) * 2009-07-02 2017-06-08 사노피 신규 2,3-디히드로-1h-이미다조(1,2-a)피리미딘-5-온 유도체, 그의 제조법 및 그의 제약 용도
MX376163B (es) 2014-05-13 2025-03-07 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
CN112574219A (zh) * 2021-01-31 2021-03-30 湖北大学 一种苯并咪唑并嘧啶酮衍生物的合成方法
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184384B1 (de) * 1984-12-06 1989-08-02 Pfizer Inc. Substituierte Dihydrochinoloncarbonsäuren und diese enthaltende antibakterielle Zusammensetzungen
AR048564A1 (es) * 1996-12-05 2006-05-10 Amgen Inc Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1184384A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
EP1295884A1 (de) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on Derivate

Also Published As

Publication number Publication date
NO20043567L (no) 2004-11-26
US7429663B2 (en) 2008-09-30
AR038620A1 (es) 2005-01-19
JP4484524B2 (ja) 2010-06-16
ZA200406154B (en) 2005-08-02
NZ534467A (en) 2006-07-28
CA2474875C (en) 2011-04-12
TWI305534B (en) 2009-01-21
EP1340759A1 (de) 2003-09-03
JP2005519087A (ja) 2005-06-30
AU2003214127C1 (en) 2009-02-05
TW200418859A (en) 2004-10-01
DE60302220D1 (de) 2005-12-15
PL372664A1 (en) 2005-07-25
US20050119280A1 (en) 2005-06-02
NO329756B1 (no) 2010-12-13
BR0308106A (pt) 2005-01-04
ES2250876T3 (es) 2006-04-16
SI1480981T1 (sl) 2006-04-30
US20080318980A1 (en) 2008-12-25
MXPA04008365A (es) 2005-07-26
WO2003072580A1 (en) 2003-09-04
EA007459B1 (ru) 2006-10-27
CN1646533A (zh) 2005-07-27
DE60302220T2 (de) 2006-07-27
AU2003214127A1 (en) 2003-09-09
AU2003214127B2 (en) 2008-07-03
CN100441581C (zh) 2008-12-10
EP1480981A1 (de) 2004-12-01
EP1480981B1 (de) 2005-11-09
KR100935262B1 (ko) 2010-01-06
IL163288A (en) 2009-12-24
CA2474875A1 (en) 2003-09-04
DK1480981T3 (da) 2006-03-20
KR20040087328A (ko) 2004-10-13
EA200400937A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
ATE362474T1 (de) Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
NO20030033L (no) Pyrido[2,3-D]pyrimidin- og pyrimido[4,5-D]pyrimidin- nukleosider
DK1699795T3 (da) Substituerede 8'-pyri(mi)dinyldihydrospiro[cycloalkylamin]-pyrimido[1,2-a]pyrimidin-6-onderivater
DK1430057T3 (da) Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater
IL180757A0 (en) Imidazo[4,5-d] pyrimidines, their uses and methods of preparation
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
IL186422A0 (en) Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
SI1480981T1 (sl) Derivati 1-(alkil), 1-(heteroaril)alkil- in 1-(aril)alkil)-7-(pirimidin-4-il)-imidazo(1,2-alfa)pirimidin-5(1H)-ona
ATE269333T1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate
WO2004106340A3 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
SI1560830T1 (sl) Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov
DK1678182T3 (da) Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
DK1315730T3 (da) 1-(alkyl)-, 1-[(heteroaryl)alkyl]-og 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-onderivater
ATE350382T1 (de) Imidazopyrimidine und triazolopyrimidine: benzodiazepinrezeptorliganden
ATE294180T1 (de) Substituierte 3,4-dihydro-pyrimido (1,2- a)pyrimidine und 3,4-dihydropyrazino (1,2- a)pyrimidine
HK1069828A (en) 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
SI1706403T1 (sl) Imidazo(4,5-c)piridin spojine in postopki antivirusnega zdravljenja
HK1085201A (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
HK1111364A (en) Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
HK1084664A (en) Pyrazolo [1,5-a] pyrimidine derivatives
HK1133653A (en) Imidazo [1,2-b] pyridazine and pyrazolo [1,5-a] pyrimidine derivatives and their use as protein kinase inhibitors
PL366807A1 (en) New derivatives of 1h-pyrazolo[4,3-e]-1,2,4-triazolo[3,4-b][1,2,4]- triazine system
HK1112850A (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480981

Country of ref document: EP